July 26 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series- OnDemand
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.
Image For Activity Cover
Availability
On-Demand
Expires on 07/31/2024
Cost
$0.00
Credit Offered
1 CME (AMA) Credit
1 CME (Other) Credit
1 Certificate of Participation Credit

First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Date of Release: July 28, 2022

Expiration Date: July 31, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date

 

Course Description

In this session, Dr. Park will be discussing several cases brought to our Vanderbilt-Ingram Cancer Center Hereditary and Oncologic Personalized Evaluation (VICC HOPE) Molecular Tumor Board to highlight how tumor/germline next-generation sequencing (NGS), along with liquid biopsies using circulating tumor DNA (ctDNA), can result in actionable findings for patients with cancer. These cases will emphasize differences in germline findings that may or may not affect clinical decision making, as well as highlight newer technologies of RNA NGS for both tumor and germline testing, that can also lead to clinical utility.

 

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Learning Objectives

At the conclusion of this session, participants should be able to:

1. Describe the difference between somatic testing with germline filtering and true germline testing

2. Demonstrate the application of RNA for tumor testing and germline testing

3. Discuss the importance of molecular tumor boards for correct interpretation of results for on label and off label use of cancer therapies

Moderator: